|
1
|
Bernstein CN, Fried M, Krabshuis JH, Cohen
H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, et al:
World gastroenterology organization practice guidelines for the
diagnosis and management of IBD in 2010. Inflamm Bowel Dis.
16:112–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su
Y, Peng L, Chen J, Yin Q, Zhao C, et al: Incidence and clinical
characteristics of inflammatory bowel disease in a developed region
of Guangdong Province, China: A prospective population-based study.
J Gastroenterol Hepatol. 28:1148–1153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao J, Ng SC, Lei Y, Yi F, Li J, Yu L,
Zou K, Dan Z, Dai M, Ding Y, et al: First prospective,
population-based inflammatory bowel disease incidence study in
mainland of China: The emergence of ‘western’ disease. Inflamm
Bowel Dis. 19:1839–1845. 2013.PubMed/NCBI
|
|
4
|
Yang H, Li Y, Wu W, Sun Q, Zhang Y, Zhao
W, Lv H, Xia Q, Hu P, Li H and Qian J: The incidence of
inflammatory bowel disease in Northern China: A prospective
population-based study. PLoS One. 9:e1012962014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye L, Cao Q and Cheng J: Review of
inflammatory bowel disease in China. Sci World J. 2013:2964702013.
View Article : Google Scholar
|
|
6
|
Arai R: Serologic markers: Impact on early
diagnosis and disease stratification in inflammatory bowel disease.
Postgrad Med. 122:177–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Satsangi J, Silverberg MS, Vermeire S and
Colombel JF: The Montreal classification of inflammatory bowel
disease: Controversies, consensus, and implications. Gut.
55:749–753. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Best WR, Becktel JM, Singleton JW and Kern
F Jr: Development of a Crohn's disease activity index. National
cooperative Crohn's disease study. Gastroenterology. 70:439–444.
1976.PubMed/NCBI
|
|
9
|
Main J, McKenzie H, Yeaman GR, Kerr MA,
Robson D, Pennington CR and Parratt D: Antibody to Saccharomyces
cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 297:1105–1106.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peyrin-Biroulet L, Standaert-Vitse A,
Branche J and Chamaillard M: IBD serological panels: Facts and
perspectives. Inflamm Bowel Dis. 13:1561–1566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rump JA, Schölmerich J, Gross V, Roth M,
Helfesrieder R, Rautmann A, Lüdemann J, Gross WL and Peter HH: A
new type of perinuclear anti-neutrophil cytoplasmic antibody
(p-ANCA) in active ulcerative colitis but not in Crohn's disease.
Immunobiology. 181:406–413. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim BG, Kim YS, Kim JS, Jung HC and Song
IS: Diagnostic role of anti-Saccharomyces cerevisiae mannan
antibodies combined with antineutrophil cytoplasmic antibodies in
patients with inflammatory bowel disease. Dis Colon Rectum.
45:1062–1069. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou F, Xia B, Wang F, Shrestha UK, Chen
M, Wang H, Shi X, Chen Z and Li J: The prevalence and diagnostic
value of perinuclear antineutrophil cytoplasmic antibodies and
anti-Saccharomyces cerevisiae antibodies in patients with
inflammatory bowel disease in mainland China. Clin Chim Acta.
411:1461–1465. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lawrance IC, Murray K, Hall A, Sung JJ and
Leong R: A prospective comparative study of ASCA and pANCA in
Chinese and caucasian IBD patients. Am J Gastroenterol.
99:2186–2194. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Papp M and Lakatos PL: Serological studies
in inflammatory bowel disease: How important are they? Curr Opin
Gastroenterol. 30:359–364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Landers CJ, Cohavy O, Misra R, Yang H, Lin
YC, Braun J and Targan SR: Selected loss of tolerance evidenced by
Crohn's disease-associated immune responses to auto- and microbial
antigens. Gastroenterology. 123:689–699. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Joossens S, Reinisch W, Vermeire S, Sendid
B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P,
Oberhuber G, et al: The value of serologic markers in indeterminate
colitis: A prospective follow-up study. Gastroenterology.
122:1242–1247. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Makharia GK, Sachdev V, Gupta R, Lal S and
Pandey RM: Anti-Saccharomyces cerevisiae antibody does not
differentiate between Crohn's disease and intestinal tuberculosis.
Dig Dis Sci. 52:33–39. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gologan S, Iacob R, Preda C, Vadan R,
Cotruta B, Catuneanu M, Iacob S, Constantinescu I, Gheorghe L,
Iobagiu S, et al: Higher titers of anti-Saccharomyces cerevisiae
antibodies IgA and IgG are associated with more aggressive
phenotypes in Romanian patients with Crohn's disease. J
Gastrointestin Liver Dis. 21:39–44. 2012.PubMed/NCBI
|
|
20
|
Zholudev A, Zurakowski D, Young W,
Leichtner A and Bousvaros A: Serologic testing with ANCA, ASCA, and
anti-OmpC in children and young adults with Crohn's disease and
ulcerative colitis: Diagnostic value and correlation with disease
phenotype. Am J Gastroenterol. 99:2235–2241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reese GE, Constantinides VA, Simillis C,
Darzi AW, Orchard TR, Fazio VW and Tekkis PP: Diagnostic precision
of anti-Saccharomyces cerevisiae antibodies and perinuclear
antineutrophil cytoplasmic antibodies in inflammatory bowel
disease. Am J Gastroenterol. 101:2410–2422. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S,
Guo Y and Zhi F: Anti-Saccharomyces cerevisiae antibodies associate
with phenotypes and higher risk for surgery in Crohn's disease: A
meta-analysis. Dig Dis Sci. 57:2944–2954. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prideaux L, De Cruz P, Ng SC and Kamm MA:
Serological antibodies in inflammatory bowel disease: A systematic
review. Inflamm Bowel Dis. 18:1340–1355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Targan SR, Landers CJ, Yang H, Lodes MJ,
Cong Y, Papadakis KA, Vasiliauskas E, Elson CO and Hershberg RM:
Antibodies to CBir1 flagellin define a unique response that is
associated independently with complicated Crohn's disease.
Gastroenterology. 128:2020–2028. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kuna AT: Serological markers of
inflammatory bowel disease. Biochem Med (Zagreb). 23:28–42. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cioffi M, Rosa AD, Serao R, Picone I and
Vietri MT: Laboratory markers in ulcerative colitis: Current
insights and future advances. World J Gastrointest Pathophysiol.
6:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X and Dong E: Anti-neutrophil
cytoplasmic antibodies in patients with inflammatory bowel
diseases. Chin J Integr Med. 3:15–18. 2000.(In Chinese).
|
|
28
|
Israeli E, Grotto I, Gilburd B, Balicer
RD, Goldin E, Wiik A and Shoenfeld Y: Anti-Saccharomyces cerevisiae
and antineutrophil cytoplasmic antibodies as predictors of
inflammatory bowel disease. Gut. 54:1232–1236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Devlin SM and Dubinsky MC: Determination
of serologic and genetic markers aid in the determination of the
clinical course and severity of patients with IBD. Inflamm. Bowel
Dis. 14:125–128, 132–133. 2008. View Article : Google Scholar
|
